IHP news 517: Access to medicines

By on April 12, 2019


Is price transparency really the answer to healthcare systems’ fiscal sustainability challenges as they strive to expand access to new technologies or even merely sustain provision within strained public budgets? Well, it depends!

A recent review of the impact of price transparency on prices and access—an input for CGD’s Working Group on the Future of Global Health Procurement – reveals a complex picture and recommends possible solutions for on-patent and off-patent pharma products. The Working group identified 5 critical questions that need to be paid attention to, and highlights a common misunderstanding of confusing purchasing power with transparent pricing.

Leave a reply
Print Friendly, PDF & Email